catalyst calendar
ABBVIE INC · Data as of 2026-10-25
H2 2026
Additional data from the Phase 3 INTREPID study, including results from a 36-week blinded extension period, are expected in 2027 and will be used to support regulatory submissions for lutikizumab in hidradenitis suppurativa in the second half of the year.Source filing
Oct 26
ABBV-706: A first-in-class SEZ6-targeted topoisomerase 1 inhibitor (Top1i)-antibody-drug conjugate (ADC) with robust antitumour activity in relapsed/refractory small cell lung cancer (R/R SCLC) Monday, October 26, 2026 10:15—10:20AM Rapid Oral Non-metastatic NSCLC and other thoracic malignancies; Burgos Auditorium – Hall 3 3837ROSource filing
Oct 26
Updated overall survival results from the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma with longer follow up Monday, October 26, 2026 12:00—12:45 PM Poster SCLC; Poster Area – Hall 5 3826PSource filing
Oct 26
Characterization of responder outcomes in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC): Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Monday, October 26, 2026 12:00—12:45 PM Poster Gynaecological cancers; Poster Area – Hall 5 1268PSource filing
Oct 26
RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): Updated results from a phase 1/2 study Monday, October 26, 2026 12:00—12:45 PM Poster NSCLC, Metastatic; Poster Area – Hall 5 2669PSource filing
Oct 26
Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs) Monday, October 26, 2026 12:00—12:45 PM Poster NSCLC, metastatic; Poster Area – Hall 5 2635PSource filing